Umbilical vs Bone Marrow Stem Cells, Liveyon Stem Cells for Regenerative Medicine

What’s the Difference? Umbilical Vs. Bone Marrow Stem Cells: Liveyon ‘Pure-Cast’ Sheds Light On The Issue

Reveals How New Technology Continues To Change Regenerative Medicine  In an experimental industry filled with misconceptions and little public understanding, the Liveyon ‘Pure-Cast’recently answered an important question in the stem cell industry: What’s the difference between Umbilical and Bone Marrow Stem Cells. Liveyon Founder and CEO John Kosolcharoen and Director of Education Dr. Alan Gaveck […]
Popular Stem Cell Questions, Liveyon Stem Cells for Regenerative Medicine

ICYMI: Liveyon Pure-Cast Answers The Most Popular Questions About Stem Cells

Created to spotlight the developing stem cell industry with an in-depth look at common misconceptions, scientific breakthroughs and advancements, and popular issues and concerns, the Liveyon Pure-Cast video podcast recently answered the most popular questions popping up around the stem cell industry. Liveyon Founder and CEO John Kosolcharoen and Director of Education Dr. Alan Gaveck […]
Stem Cell Industry, Liveyon Stem Cells for Regenerative Medicine

‘Is There A Stem Cell Bubble?’ Liveyon CEO, Education Director Discuss The State Of The Regenerative Industry

Insiders Provide Real Solutions To The Tough Problems Plaguing The Industry In a recent episode of the Liveyon ‘Pure-Cast,’ John Kosolcharoen, founder and CEO of Liveyon, and Dr. Alan Gaveck, Director of Education, examined the state of the regenerative industry—breaking down some of the most pressing problems plaquing the stem cell field and offering real […]
Liveyon Stem Cell Pure Product, Liveyon Stem Cells for Regenerative Medicine

Liveyon PURE® Debuts Clinical Trial Grade Stem Cell Concentrate Derived from Umbilical Cord Blood

Liveyon Labs Sets New Industry Standard for Characterization and Consistency in Live Total Nucleated Cell Counts, Viability, Purity and Safety   YORBA LINDA, Calif. – February 28, 2019 – Liveyon, the global leader in regenerative medicine, today announced the availability of Liveyon PURE®, a clinical trial grade stem cell concentrate derived from umbilical cord blood. […]
Liveyon FDA Recall, Liveyon Pure Cast Podcast, Stem Cells for Regenerative Medicine

From Recall to Rebirth: Liveyon Ready to Reinvent Regenerative Medicine

 For more Liveyon Pure Cast Podcast videos subscribe to our YouTube channel at: Behind-the-Scenes Look at Events Surrounding FDA Recall of Genetech Products and Plans for Liveyon to Produce its Own Stem Cell Concentrate Derived from Umbilical Cord Blood. YORBA LINDA, Calif. – February 26th, 2019 – For many companies in the fledgling stem […]
 

 

Medical Professional Viewing Only (Disclaimer)</font color>


This site was intended for education purposes only and strictly for use by medical professionals. The FDA recently re-confirmed, there is only one registered stem cell product, and while there is enormous promise in stem cell therapies, and thousands of ongoing experimental applications trying to establish efficacy, these are not at the point where they would meet the scientific standard.
The FDA has stated:
Stem cells, like other medical products that are intended to treat, cure or prevent disease, generally require FDA approval before they can be marketed. FDA has not approved any stem cell-based products for use, other than cord blood-derived hematopoietic progenitor cells (blood forming stem cells) for certain indications.
http://www.fda.gov/AboutFDA/Transparency/Basics/ucm194655.htm
This site is not intended for consumers.
If you are considering stem cell treatment in the U.S., ask your physician if the necessary FDA approval has been obtained or if you will be part of an FDA-regulated clinical study. This also applies if the stem cells are your own. Even if the cells are yours, there are safety risks, including risks introduced when the cells are manipulated after removal.
“There is a potential safety risk when you put cells in an area where they are not performing the same biological function as they were when in their original location in the body.” Cells in a different environment may multiply, form tumors, or may leave the site you put them in and migrate somewhere else.
If you are considering having stem cell treatment in another country, learn all you can about regulations covering the products in that country. Exercise caution before undergoing treatment with a stem cell-based product in a country that—unlike the U.S.—may not require clinical studies designed to demonstrate that the product is safe and effective. FDA does not regulate stem cell treatments used solely in countries other than the United States and typically has little information about foreign establishments or their stem cell products.
http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm286155.htm
Stem cell therapies have enormous promise, but the science in each use is still in the developmental stage. Professional judgment and expertise is needed in using stem cells for any therapeutic use, and we urge anyone embarking on the use of stem cell therapies to consult the national health data bases to evaluate current information from clinical trials and the FDA websites on human tissue should also be consulted to get its current evaluation of any therapy.